207 related articles for article (PubMed ID: 29961603)
21. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
[TBL] [Abstract][Full Text] [Related]
22. Healthcare resource utilization and costs in 23-25-year-old women with human papillomavirus (HPV) associated anogenital diseases in Germany - a retrospective analysis of statutory health insurance claims data.
Reuschenbach M; Mihm S; Wölle R; Schneider KM; Jacob C; Greiner W; Hampl M; Goodman E
BMC Health Serv Res; 2022 Aug; 22(1):1002. PubMed ID: 35932066
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and socioeconomic burden of diabetes mellitus in South Korean adults: a population-based study using administrative data.
Oh SH; Ku H; Park KS
BMC Public Health; 2021 Mar; 21(1):548. PubMed ID: 33743612
[TBL] [Abstract][Full Text] [Related]
24. Incidence, cost and gender differences of oropharyngeal and noncervical anogenital cancers in South Korea.
Choi I; Lee D; Son KB; Bae S
BMC Public Health; 2020 Jun; 20(1):1035. PubMed ID: 32600300
[TBL] [Abstract][Full Text] [Related]
25. The cost-effectiveness of male HPV vaccination in the United States.
Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and socio-economic burden of heart failure in an aging society of South Korea.
Lee H; Oh SH; Cho H; Cho HJ; Kang HY
BMC Cardiovasc Disord; 2016 Nov; 16(1):215. PubMed ID: 27832754
[TBL] [Abstract][Full Text] [Related]
28. Influencing Factors of Transportation Costs Regarding Healthcare Service Utilization in Korea.
Jang SY; Seon JY; Oh IH
J Korean Med Sci; 2020 Sep; 35(35):e290. PubMed ID: 32893520
[TBL] [Abstract][Full Text] [Related]
29. Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium.
Annemans L; Rémy V; Lamure E; Spaepen E; Lamotte M; Muchada JP; Largeron N
J Med Econ; 2008; 11(1):135-50. PubMed ID: 19450115
[TBL] [Abstract][Full Text] [Related]
30. Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation.
Insinga RP; Dasbach EJ; Allen SE; Carides GW; Myers ER
Value Health; 2008 Dec; 11(7):1022-32. PubMed ID: 18489503
[TBL] [Abstract][Full Text] [Related]
31. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
[TBL] [Abstract][Full Text] [Related]
33. Economic Burden of Osteoporosis in South Korea: Claim Data of the National Health Insurance Service from 2008 to 2011.
Ha YC; Kim HY; Jang S; Lee YK; Kim TY
Calcif Tissue Int; 2017 Dec; 101(6):623-630. PubMed ID: 28913546
[TBL] [Abstract][Full Text] [Related]
34. Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States.
Clay PA; Thompson TD; Markowitz LE; Ekwueme DU; Saraiya M; Chesson HW
Vaccine; 2023 Mar; 41(14):2376-2381. PubMed ID: 36907737
[TBL] [Abstract][Full Text] [Related]
35. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
[TBL] [Abstract][Full Text] [Related]
36. The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting.
Sharma M; Sy S; Kim JJ
BJOG; 2016 May; 123(6):917-26. PubMed ID: 26176301
[TBL] [Abstract][Full Text] [Related]
37. The Estimated Lifetime Medical Cost of Diseases Attributable to Human Papillomavirus Infections Acquired in 2018.
Chesson HW; Laprise JF; Brisson M; Martin D; Ekwueme DU; Markowitz LE
Sex Transm Dis; 2021 Apr; 48(4):278-284. PubMed ID: 33492104
[TBL] [Abstract][Full Text] [Related]
38. Hospital resource utilisation from HPV-related diseases in England: a real-world cost analysis.
Fabiano G; Marcellusi A; Mennini FS; Sciattella P; Favato G
Eur J Health Econ; 2023 Feb; 24(1):75-80. PubMed ID: 35551568
[TBL] [Abstract][Full Text] [Related]
39. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK.
Brown RE; Breugelmans JG; Theodoratou D; Bénard S
Curr Med Res Opin; 2006 Apr; 22(4):663-70. PubMed ID: 16684427
[TBL] [Abstract][Full Text] [Related]
40. Economic burden of cervical cancer and premalignant lesions associated with human papilloma virus: a societal perspective.
Lotfi F; Khodabandeh F; Jafari A; Rezaee M; Rahimi H; Shiravani Z; Keshavarz K
Expert Rev Pharmacoecon Outcomes Res; 2023 Apr; 23(4):439-447. PubMed ID: 36876411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
